contemporarypediatrics3d
FDA approves levacetylleucine for the treatment of Niemann-Pick disease, type C
On average, participants treated with levacetylleucine for 12 weeks had better fSARA scores compared to when they received a placebo. The FDA has recently approved levacetylleucine (Aqneursa; IntraBio ...
contemporarypediatrics3d
Offspring seizure risk associated with maternal influenza
In a recent study, infants of mothers with an influenza infection during pregnancy were significantly more likely to experience febrile seizures, but not epilepsy. The risk of childhood seizures is ...
contemporarypediatrics4d
Epinephrine nasal spray now available to treat type 1 allergic reactions, anaphylaxis
The needle-free option to treat type 1 allergic reactions, including anaphylaxis, was approved for adults and children who weigh 66 lbs or more on August 9, 2024. Epinephrine nasal spray (neffy; ARS ...
contemporarypediatrics4d
FDA accepts roflumilast's sNDA to treat scalp and body psoriasis in adolescents, adults
With this acceptance, the federal agency has assigned a PDUFA date of May 22, 2025 for roflumilast foam (Zoryve) 0.3%. Results from the phase 3 ARRECTOR trial, a phase 2b study, and long-term efficacy ...
contemporarypediatrics5d
Technology: How far we have come and how far can we go?
In her September 2024 article, Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights the potential of digital health tools to improve care for pediatric mental health, obesity, and ...
contemporarypediatrics8d
FDA approves FluMist for self- or caregiver-administration
With this approval, FluMist becomes the first vaccine to prevent influenza that does not need to be administered by a health care provider. Influenza Vaccine Live (FluMist; AstraZeneca) is now FDA ...
contemporarypediatrics8d
FDA approves arimoclomol as first drug to treat Neimann-Pick disease, type C
The approval is indicated for adults and children aged 2 years and older, making arimoclomol (Miplyffa) the first drug approved by the FDA to treat NPC. The FDA has approved the first drug to treat ...
contemporarypediatrics9d
Exploring associations of inpatient food insecurity and pediatric hospitalizations
Previous research has associated poor health outcomes and increased health care use with household food insecurity (HFI), which can be dependent on context and environmental stressors, such as ...
contemporarypediatrics9d
Comparing safety of JAK inhibitors between adolescent, adult patient
Pediatric patients treated with Janus kinase inhibitors (JAKi) reporting adverse events (AEs) report higher numbers of lymphatic and blood disorders, recent findings suggest, whereas adults aged 18 ...
contemporarypediatrics10d
Low-food access in early life associated with higher subsequent child BMI, obesity risk
In a recently-published study, results demonstrated that residence in low-income, low-food access neighborhoods in early life was linked to higher subsequent child body mass index (BMI) and higher ...
contemporarypediatrics10d
FDA grants Breakthrough Therapy to oral infigratinib for children with achondroplasia
The FDA has granted Breakthrough Therapy Designation for oral infigratinib (BridgeBio Pharma), which is currently under development for children with achondroplasia, according to a press release from ...
contemporarypediatrics11d
First-generation antihistamine prescriptions linked to higher seizure risk in children
First-generation antihistamine prescriptions were linked to a 22% higher seizure risk in young children, especially those aged 6 to 24 months, according to recent findings. First-generation ...